As detailed below, novel immunotherapies targeting B7-H3 are considered very promising in enhancing the clinical response and overcoming resistance in NSCLC patients, including the use of chimeric antigen receptor (CAR)-T cells (192). Here, CD276 is linked to non-small cell lung carcinoma.